Insulin Lispro Update

The Diabetes Educator

Volumn 28, Issue 2, 2002, Pages 269-277

  Meece, Jerry D ^a   Campbell, R Keith ^b  

^a Clinical Services at Plaza Pharmacy and Wellness Center ^*  (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN LISPRO;

ARTICLE; BLOOD; CHILD; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEDLINE; METABOLISM;

BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MEDLINE;

EID: 0036511999     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/014572170202800212     Document Type: Article

References (18)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
4. Howey DC, Bowsher RR, Rocco LB, Woodworth JR. Lys pro human insulin. Diabetes. 1994;43:396-402.
5. Campbell RK, White JR, Nomura D. The clinical importance of postprandial hyperglycemia. US Pharmacist. 2000;23:12-12.
6. Fuller JH, Shipley MJ, Rose G. Coronary heart disease risk and impaired glucose tolerance: the Whitehall Study. Lancet. 1980;1:1373-1376.
7. Hanefed M, Fischer S, Julius U. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.
8. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617-621.
9. Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies towards improved control during insulin lispro therapy in IDDM: importance of basal insulin. Diabetes Care. 1997;20:1287-1289.
10. Heller, SR, Amiel SA, Janes J. Hypoglycemia during intensive insulin therapy: a comparison of lispro and regular insulin. Diabetes. 1997;(suppl 1):A151-A151.
11. Anderson JH Jr., Brunelle R, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin. Diabetes. 1997;46:265-270.
12. Woodworth JR, Howey D, Bowsher R, Lutz S, Santa P, Brady P. Lys(B28), pro(B29) human insulin: dose ranging vs. Humulin R [abstract]. Diabetes. 1993;42(suppl 1):54A-54A.
13. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with Humalog in variable combination with NPH insulin at bedtime. Diabetes Care. 1999;22:468-477.
14. Schernthaner G, Wein W, Sandholzer K, Equiliz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro: a new therapeutic option for type 1 diabetic patients. Diabetes Care. 1998;21:570-573.
15. Garg SK, Pennington M, Gottlieb P, Anderson J, Jennings K, Robinson J. Comparison of maternal and fetal outcomes between human regular and Humalog insulin treated pregnancies in type 1 diabetes. Diabetes. 1999;48(suppl 1):A61-A61.
16. Jovanovic L, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care. 1999;22:1422-1427.
17. Koivisto VA, Tuominen JA, Ebeling P, et al. Humalog mix 25 insulin as a pre-meal therapy in type 11 diabetic patients. Diabetes Care. 1999;22:459-462.
18. Data on file. 1999. Eli Lilly & Co, Indianapolis, Ind.